Shares of Cipla Ltd. saw a significant rise on Monday after global brokerage firm Citi maintained its 'Buy' rating and set a target price of Rs 1,700, indicating a potential upside of nearly 26% from current levels. The pharmaceutical major was also placed on Citi's 90-day positive catalyst watch, signaling strong confidence in its near-term prospects.
Key US Business Catalysts Expected
Citi's optimistic outlook is largely fueled by several anticipated developments in Cipla's US business. Analysts point to the potential approval of generic Flovent and the expected launch of generic Ventolin as significant near-term triggers. Additionally, Cipla's expanding presence in the Nintedanib market, where its market share is approaching 50%, is seen as a strong growth driver.
The brokerage highlighted that Cipla's recent earnings beat was primarily due to stronger-than-anticipated operating margins, which contributed significantly to the positive surprise.
Resilient India Business and Regulatory Watch
Beyond its international ventures, Cipla's India business continues to be a crucial pillar of its financial strength. The domestic market consistently demonstrates healthy growth, particularly benefiting from a rebound in the respiratory portfolio. This segment contributes nearly two-thirds of the company's EBITDA, underscoring its importance to overall earnings.
Another factor closely monitored by Citi is the regulatory review of Cipla's Indore manufacturing facility. A positive outcome from the re-inspection, potentially leading to clearance from the USFDA, is expected to substantially improve market sentiment towards the stock.
Valuation and Market Position
Citi's analysis notes that Cipla is currently trading at approximately 25 times its estimated FY27 earnings and 21 times its FY28 earnings. While these multiples suggest a premium valuation, the brokerage considers the stock attractively priced. This assessment is based on Cipla's stronger exposure to the domestic market compared to several peers who command even higher valuations, reinforcing its stable position in the pharmaceutical sector.